USC Norris Comprehensive Cancer Center

Genomic and Epigenomic Regulation Program

The Genomic and Epigenomic Regulation Program (GER), formerly named the Epigenetics and Regulation Program, focuses on the mechanisms by which cellular genomes, epigenomes, genes, and pathways are maintained and regulated, and how normal regulation is disrupted in cancer.  The overarching mission of the GER program is to discover basic mechanisms of genomic and epigenomic regulation involved in growth and behavior of normal and cancer cells, and translating basic findings into cancer, detection, prognosis, and treatment in collaboration with other USC Norris programs. GER members focus their research on tumor types that represent significant cancer burdens and disparities in our catchment area, including prostate, breast, colorectal, lung, liver cancer, and acute lymphoblastic leukemia (ALL).

The program has two specific aims:

      1. Characterize the genomic, epigenomic, and transcriptomic features that are distinct in cancer cells relative to normal cells.
      2. Define mechanisms that regulate these cancer features at the chromatin, DNA, and RNA level to identify novel potential therapeutic targets.

The program is led by Michael Stallcup, PhD, a leading researcher in discovering and characterizing transcriptional coregulators, and Yali Dou, PhD, known for translation of epigenetic discoveries into novel inhibitors. The program brings together 37 members from 18 departments and five schools. GER members lead 3 P and U grants and participate, along with members of all five Programs, in a new NCI U54 Health Equity Center led by TACS and Cancer Epidemiology members. Additionally, GER members participate in several PhD and MS programs that span the USC community and lead two R25 training programs.